This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics' CEO Discusses F4Q12 Results - Earnings Call Transcript

Myriad Genetics, Inc. (MYGN)

F4Q12 Earnings Conference Call

August 14, 2012 4:30 PM ET


Rebecca Chambers – Director of Investor Relations

Peter D. Meldrum – President and Chief Executive Officer

Mark C. Capone – President, Myriad Genetic Laboratories

James S. Evans – Chief Financial Officer and Treasurer


Scott Gleason – Stephens Inc.

Jon Wood – Jefferies & Company, Inc.

Amanda Murphy - William Blair

Michael Yee - RBC Capital Markets

Joel - Goldman Sachs

Sean Rodriguez - Cowen & Company

Derik de Bruin - Bank of America

William Quirk - Piper Jaffray

Tycho Peterson – JPMorgan

Dan Leonard - Leerink Swann



Ladies and gentlemen, thank you for standing by. Welcome to the Myriad Genetics' 2012 Fourth Quarter and Fiscal year-end Earnings Call. During the presentation, all participants will be in a listen-only-mode. Afterwards, we will conduct the question-and-answer session. (Operator instructions). As a reminder, this conference is being recorded Tuesday, August 14, 2012.

I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead.

Rebecca Chambers

Thank you, Susan. Good afternoon, everyone, and welcome to the Myriad Genetics' fourth quarter and fiscal year 2012 earnings call. During the call, we will review the financial results we've released today and detail our expectations for fiscal 2013, after which we will host the question-and-answer session. If you have not had a chance to review the earnings release, it can be found in the Investor Relations section of our website at

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,009.31 -25.62 -0.14%
S&P 500 2,104.03 +3.63 0.17%
NASDAQ 5,019.7440 +25.1420 0.50%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs